These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 38824626

  • 21. Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder.
    Shafrin J, Shrestha A, Chandra A, Erder MH, Sikirica V.
    Health Econ; 2017 Nov; 26(11):1459-1466. PubMed ID: 27620206
    [Abstract] [Full Text] [Related]

  • 22. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
    Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, Hsieh SC, Bai Z, Hossain A, Skidmore B, Tsakonas E, Chojecki D, Mamdani M, Wells GA.
    PLoS One; 2020 Nov; 15(10):e0240584. PubMed ID: 33085721
    [Abstract] [Full Text] [Related]

  • 23. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [Abstract] [Full Text] [Related]

  • 24. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
    Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA.
    Eur J Health Econ; 2018 Jan; 19(1):21-35. PubMed ID: 28093662
    [Abstract] [Full Text] [Related]

  • 25. Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials.
    Adler LA, Adams J, Madera-McDonough J, Kohegyi E, Hobart M, Chang D, Angelicola M, McQuade R, Liebowitz M.
    J Clin Psychopharmacol; 2018 Jan; 42(5):429-439. PubMed ID: 35652746
    [Abstract] [Full Text] [Related]

  • 26. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
    Pozzi M, Carnovale C, Mazhar F, Peeters GGAM, Gentili M, Nobile M, Radice S, Clementi E.
    J Clin Psychopharmacol; 2019 Jan; 39(4):386-392. PubMed ID: 31205193
    [Abstract] [Full Text] [Related]

  • 27. Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder.
    Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Fukushi A, Saito K.
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):21-31. PubMed ID: 31718254
    [Abstract] [Full Text] [Related]

  • 28. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.
    Steer C, Froelich J, Soutullo CA, Johnson M, Shaw M.
    CNS Drugs; 2012 Aug 01; 26(8):691-705. PubMed ID: 22762726
    [Abstract] [Full Text] [Related]

  • 29. Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients.
    Childress A, Sottile R, Khanbijian S.
    Expert Rev Neurother; 2023 Aug 01; 23(11):945-953. PubMed ID: 37846759
    [Abstract] [Full Text] [Related]

  • 30. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C, 31001074-ATT2001 Study Investigators.
    CNS Drugs; 2012 May 01; 26(5):421-34. PubMed ID: 22519922
    [Abstract] [Full Text] [Related]

  • 31. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
    Frampton JE.
    Drugs; 2018 Jul 01; 78(10):1025-1036. PubMed ID: 29923015
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder.
    Childress AC, Lloyd E, Jacobsen L, Gunawardhana L, Johnson SA, Findling RL.
    J Am Acad Child Adolesc Psychiatry; 2022 Dec 01; 61(12):1423-1434. PubMed ID: 35577034
    [Abstract] [Full Text] [Related]

  • 33. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, Biederman J, 303 Study Group.
    J Clin Psychiatry; 2008 Sep 01; 69(9):1364-73. PubMed ID: 19012818
    [Abstract] [Full Text] [Related]

  • 34. Viloxazine ER (Qelbree) for ADHD.
    Med Lett Drugs Ther; 2021 Jun 28; 63(1627):98-100. PubMed ID: 34181631
    [No Abstract] [Full Text] [Related]

  • 35. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.
    J Manag Care Pharm; 2007 Sep 28; 13(7):561-9. PubMed ID: 17874862
    [Abstract] [Full Text] [Related]

  • 36. A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, Chowdhry F, Cutler AJ, Jones NJ, Findling RL, Schwabe S.
    J Clin Psychopharmacol; 2007 Sep 28; 41(4):370-380. PubMed ID: 34181360
    [Abstract] [Full Text] [Related]

  • 37. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
    Dittmann RW, Cardo E, Nagy P, Anderson CS, Adeyi B, Caballero B, Hodgkins P, Civil R, Coghill DR.
    CNS Drugs; 2014 Nov 28; 28(11):1059-69. PubMed ID: 25038977
    [Abstract] [Full Text] [Related]

  • 38. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y, Yang L, Stein MA, Cao Q, Wang Y.
    J Child Adolesc Psychopharmacol; 2016 May 28; 26(4):362-71. PubMed ID: 26779845
    [Abstract] [Full Text] [Related]

  • 39. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
    Wietecha LA, Clemow DB, Buchanan AS, Young JL, Sarkis EH, Findling RL.
    CNS Neurosci Ther; 2016 Jul 28; 22(7):546-57. PubMed ID: 26922462
    [Abstract] [Full Text] [Related]

  • 40. Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.
    Faraone SV, Gomeni R, Hull JT, Chaturvedi SA, Busse GD, Melyan Z, O'Neal W, Rubin J, Nasser A.
    Psychiatry Res; 2022 Dec 28; 318():114922. PubMed ID: 36375329
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.